Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Inclusion Criteria

• •Are ≥18 years of age at screening.
• •Have a clinical diagnosis of TED associated with active, moderate to severe TED with the following at screening and Visit 0:
• •* A CAS ≥ 4 in either eye, and
• •* Clinical evidence of worsened proptosis with:
• •1. Proptosis ≥ 18 mm and/or
• •2. Proptosis ≥ 3 mm increase from participant's baseline (prior to diagnosis of TED), as estimated by the Investigator/assessor
• •Have moderate to severe active TED, as defined by European Group on Graves' Orbitopathy (EUGOGO) guidelines.
• •Have onset of active TED within 12 months prior to screening.
• •Have documented evidence of detectable anti-TSHR-Ab at screening.
• •Are not expected to require immediate surgical intervention and are not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
• •Are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism.